Cargando…

A systematic comparison of different composite measures (DAS 28, CDAI, SDAI, and Boolean approach) for determining treatment effects on low disease activity and remission in rheumatoid arthritis

BACKGROUND: Some composite measures for determining the treatment effects of disease-modifying antirheumatic drugs on remission and low disease activity (LDA) in rheumatoid arthritis (RA) may produce misleading results if they include an acute phase reactant (APR). To inform the choice of appropriat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Janke, Kirsten, Kiefer, Corinna, McGauran, Natalie, Richter, Bernd, Krause, Dietmar, Wieseler, Beate
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732992/ https://www.ncbi.nlm.nih.gov/pubmed/36482451 http://dx.doi.org/10.1186/s41927-022-00314-7

Ejemplares similares

Reliability and validity of CDAI and SDAI indices in comparison to DAS-28 index in Moroccan patients with rheumatoid arthritis
por: Slama, Imane Ben, et al.
Publicado: (2015)

Centralised Full Access to Clinical Study Data Can Support Unbiased Guideline Development, Continuing Medical Education, and Patient Information
por: McGauran, Natalie, et al.
Publicado: (2021)

From publication bias to lost in information: why we need a central public portal for clinical trial data
por: Wieseler, Beate, et al.
Publicado: (2022)

Access to regulatory data from the European Medicines Agency: the times they are a-changing
por: Wieseler, Beate, et al.
Publicado: (2012)

The MIDAS SDAI implementation
por: Thomas, D, et al.
Publicado: (1996)

The DAS28-ESR cutoff value necessary to achieve remission under the new Boolean-based remission criteria in patients receiving tocilizumab
por: Hirabayashi, Yasuhiko, et al.
Publicado: (2012)

Reporting bias in medical research - a narrative review
por: McGauran, Natalie, et al.
Publicado: (2010)

Impact of Inclusion of Industry Trial Results Registries as an Information Source for Systematic Reviews
por: Potthast, Regine, et al.
Publicado: (2014)

Comparative effectiveness of biological medicines in rheumatoid arthritis: systematic review and network meta-analysis including aggregate results from reanalysed individual patient data
por: Janke, Kirsten, et al.
Publicado: (2020)

DAS28‐CRP Cutoffs for High Disease Activity and Remission Are Lower Than DAS28‐ESR in Rheumatoid Arthritis
por: Greenmyer, Jacob R., et al.
Publicado: (2020)

Validation of the Simplified Disease Activity Index (SDAI) with a quick quantitative C-reactive protein assay (SDAI-Q) in patients with rheumatoid arthritis: a prospective multicenter cross-sectional study
por: Schally, Julia, et al.
Publicado: (2022)

Completeness of Reporting of Patient-Relevant Clinical Trial Outcomes: Comparison of Unpublished Clinical Study Reports with Publicly Available Data
por: Wieseler, Beate, et al.
Publicado: (2013)

Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study
por: Lee, Yvonne C, et al.
Publicado: (2011)

Response to 'Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study'
por: Yoshida, Kazuki, et al.
Publicado: (2011)

Silent progression in patients with rheumatoid arthritis: is DAS28 remission an insufficient goal in RA? Results from the German Remission-plus cohort
por: Sewerin, Philipp, et al.
Publicado: (2017)

Combined use of CDAI and blood indices for assessing endoscopic activity in ileocolic Crohn’s disease
por: Hu, Xiaolin, et al.
Publicado: (2023)

Comparative Efficacy (DAS28 Remission) of Targeted Immune Modulators for Rheumatoid Arthritis: A Network Meta-Analysis
por: Best, Jennie H., et al.
Publicado: (2021)

Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports
por: Köhler, Michael, et al.
Publicado: (2015)

Comparison of Disease Activity Score in 28 joints with ESR (DAS28), Clinical Disease Activity Index (CDAI), Health Assessment Questionnaire Disability Index (HAQ-DI) & Routine Assessment of Patient Index Data with 3 measures (RAPID3) for assessing disease activity in patients with rheumatoid arthritis at initial presentation
por: Kumar, B. Siddhartha, et al.
Publicado: (2017)

DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable
por: Fleischmann, Roy M, et al.
Publicado: (2017)

Discrepancies in assessment of patients with rheumatoid arthritis and secondary Sjögren's syndrome by DAS28-ESR and DAS28-CRP
por: Romanowska-Próchnicka, Katarzyna, et al.
Publicado: (2016)

Assumptions of Mixed Treatment Comparisons in Health Technology Assessments - Challenges and Possible Steps for Practical Application
por: Reken, Stefanie, et al.
Publicado: (2016)

Gender stratified adjustment of the DAS28-CRP improves inter-score agreement with the DAS28-ESR in rheumatoid arthritis
por: Hamann, Philip D H, et al.
Publicado: (2019)

Use of rheumatoid arthritis impact of disease (RAID) in routine care; identification of DAS28 remission and unmet patient-reported outcomes
por: Mistry, Jatin, et al.
Publicado: (2020)

Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition
por: Schoels, M., et al.
Publicado: (2017)

Predictor of the Simplified Disease Activity Index 50 (SDAI 50) at Month 3 of bDMARD Treatment in Patients with Long-Established Rheumatoid Arthritis
por: Miwa, Yusuke, et al.
Publicado: (2017)

Disagreement in primary study selection between systematic reviews on negative pressure wound therapy
por: Peinemann, Frank, et al.
Publicado: (2008)

Negative pressure wound therapy: Potential publication bias caused by lack of access to unpublished study results data
por: Peinemann, Frank, et al.
Publicado: (2008)

Limiting factors to Boolean remission differ between autoantibody-positive and -negative patients in early rheumatoid arthritis
por: Bugatti, Serena, et al.
Publicado: (2021)

On Boolean posets of numerical events
por: Dorninger, Dietmar, et al.
Publicado: (2021)

Boolean differential equations
por: Steinbach, Bernd, et al.
Publicado: (2013)

Harmonizing Medicine and Surgery in the Pursuit of Boolean Remission: A Rheumatological Magnum Opus
por: Rehman, Abdur, et al.
Publicado: (2023)

Validity and risk of adopting PGA ≤ 2 as a remission criteria of Boolean in clinical practice in patient with rheumatoid arthritis
por: Yoshii, Ichiro, et al.
Publicado: (2022)

The impact of time length to Boolean remission for tight disease activity control after acquisition in rheumatoid arthritis patients
por: Yoshii, Ichiro, et al.
Publicado: (2023)

The association of anti-CCP1 antibodies with disease activity score 28 (DAS-28) in rheumatoid arthritis
por: Karimifar, Mansoor, et al.
Publicado: (2012)

Validation of methods for converting the original Disease Activity Score (DAS) to the DAS28
por: Carpenter, Lewis, et al.
Publicado: (2018)

Boolean differential calculus
por: Steinbach, Bernd, et al.
Publicado: (2017)

Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab
por: Hirata, Shintaro, et al.
Publicado: (2015)

DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment
por: Vander Cruyssen, Bert, et al.
Publicado: (2005)

Using a DAS28-CRP-steered treat-to-target strategy does not eliminate subclinical inflammation as assessed by ultrasonography in rheumatoid arthritis patients in longstanding clinical remission
por: Terslev, Lene, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8rvatq890tuk9u6q0n46k5k0j6